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DrOBJECTIVES This study sought to investigate the clinical outcomes based on the assessment of quantitative coronary
angiography–maximal lumen diameter (Dmax).
BACKGROUND Assessment of pre-procedural Dmax of proximal and distal sites has been used for Absorb scaffold size
selection in the ABSORB studies.
METHODS A total of 1,248 patients received Absorb scaffolds in the ABSORB Cohort B (ABSORB Clinical Investigation,
Cohort B) study (N ¼ 101), ABSORB EXTEND (ABSORB EXTEND Clinical Investigation) study (N ¼ 812), and ABSORB II
(ABSORB II Randomized Controlled Trial) trial (N ¼ 335). The incidence of major adverse cardiac events (MACE) (a
composite of cardiac death, any myocardial infarction [MI], and ischemia-driven target lesion revascularization) was
analyzed according to the Dmax subclassiﬁcation of scaffold oversize group versus scaffold nonoversize group.
RESULTS Of 1,248 patients, pre-procedural Dmax was assessed in 1,232 patients (98.7%). In 649 (52.7%) patients, both
proximal and distal Dmax values were smaller than the nominal size of the implanted scaffold (scaffold oversize group),
whereas in 583 (47.3%) of patients, the proximal and/or distal Dmax were larger than the implanted scaffold (scaffold
nonoversize group). The rates of MACE and MI at 1 year were signiﬁcantly higher in the scaffold oversize group than in the
scaffold nonoversize group (MACE 6.6% vs. 3.3%; log-rank p < 0.01, all MI: 4.6% vs. 2.4%; log-rank p ¼ 0.04), mainly
driven by a higher MI rate within 1 month post-procedure (3.5% vs. 1.9%; p¼ 0.08). The independent MACE determinants
were both Dmax smaller than the scaffold nominal size (odds ratio [OR]: 2.13, 95% conﬁdence interval [CI]: 1.22 to 3.70;
p < 0.01) and the implantation of overlapping scaffolds (OR: 2.10, 95% CI: 1.17 to 3.80; p ¼ 0.01).
CONCLUSIONS Implantation of an oversized Absorb scaffold in a relatively small vessel appears to be associated with a
higher 1-year MACE rate driven by more frequent early MI. (ABSORB Clinical Investigation, Cohort B [ABSORB Cohort B],
NCT00856856; ABSORB EXTEND Clinical Investigation [ABSORB EXTEND], NCT01023789; ABSORB II Randomized
Controlled Trial [ABSORB II], NCT01425281) (J Am Coll Cardiol Intv 2015;8:1715–26) © 2015 by the American College of
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1716T he performance of the second-generation Absorb bioresorbableeverolimus-eluting scaffold was in-
vestigated in the ABSORB II (ABSORB II Ran-
domized Controlled Trial) as well as in the
Cohort B1, Cohort B2, and ABSORB EXTEND
(ABSORB EXTEND Clinical Investigation)
studies, and demonstrated excellent clinical
results (1–7). As the Absorb scaffold has a
strict upper limit of expansion, quantitative
coronary angiography (QCA)-guided implan-
tation was a mandatory requirement in
ABSORB EXTEND (7) and ABSORB II (1). The
aim was to allow the selection of a scaffold
size matching that of the reference vessel
diameter. For reasons related to the poten-
tial labeling by the regulator, the sponsoring
corporation did not want to require the use
of intravascular imaging for sizing the vessel
and for selection of the device size. The con-
cerns about appropriate deployment of the
Absorb scaffold with angiography guidance
arose mainly from optical coherence tomog-
raphy (OCT) substudies demonstrating anincreased frequency of malapposition when the
Absorb scaffold was implanted in a too large vessel
(8). Another matter of concern is the risk of scaffold
disruption (9), particularly when the device has
already reached its maximal limit of expansion and
is overexpanded in an attempt to correct persistent
malapposition. Conversely, an OCT substudy showed
an excess of proximal and/or distal edge dissections
when the Absorb scaffold was implanted in vessels
smaller than the device nominal size (8). However,
the impact of quantitative angiographic guidance on
clinical outcomes is so far unknown. Therefore, the
aim of this study was to investigate the relationship
between clinical outcomes and maximal diameter
(Dmax) by QCA, which was used as a guide for appro-
priate selection and deployment of the Absorb scaf-
fold in 2 cohorts of patients from the ABSORB
Cohort B study, ABSORB EXTEND study, and ABSORB
II trial.METHODS
STUDY DESIGN AND POPULATION. We analyzed the
results of Absorb scaffold implantation in 1,248of Abbott Vascular. All other authors have reported that they ha
sclose.
received June 1, 2015; revised manuscript received July 21, 2015patients enrolled between 2009 and 2013 in the
ABSORB Cohort B study (2,4), ABSORB EXTEND study
(7), and ABSORB II (1) randomized controlled trial.
The design of each study is described elsewhere
(4,6,7,10). In the ABSORB Cohort B, a 3.0  18-mm
Absorb scaffold only was available. In the ABSORB
EXTEND and ABSORB II studies, patients were
treated as follows (1,7): 1) a 3.5-mm Absorb scaffold
was used when both the proximal and distal Dmax
were within an upper limit of 3.8 mm and a lower
limit of 3.0 mm: 2) a 3.0-mm Absorb scaffold was used
when both the proximal and distal maximal lumen
diameters were within an upper limit of 3.3 mm and a
lower limit of 2.5 mm: 3) a 2.5-mm Absorb scaffold
was used when both the proximal and the distal
Dmax were within an upper limit of 3.0 mm and a
lower limit of 2.25 mm: and 4) scaffold overlap was
allowed. Patients demographic data and baseline
characteristics were similar among 3 studies as well as
pre-procedure minimal lumen diameter (MLD) and %
diameter stenosis. All of these trials were sponsored
and funded by Abbott Vascular. The research ethics
committee of each participating institution approved
the protocol, and all enrolled patients provided
written informed consent before inclusion.
STUDY DEVICE. The details of the study device
(Absorb, Abbott Vascular, Santa Clara, California)
have been described in detail previously (5,6). In
brief, the balloon-expandable Absorb scaffold com-
prises a poly-L-lactide backbone (6) coated with an
amorphous drug-eluting coating matrix composed of
poly-D,L-lactide polymer containing everolimus.
QCA ANALYSIS. QCA guidance of Absorb implanta-
tion relies on the angiographic diameter function
curve of the pre-treatment vessel segment that con-
tains 3 nonambiguous data points; namely, the MLD
and the Dmax with respect to the MLD of the proximal
(proximal Dmax) and distal (distal Dmax) vessel seg-
ments of interest (8,11) (Figure 1). QCA analyses were
undertaken by the sites before Absorb implantation,
and post-procedurally by an independent core labo-
ratory (Cardialysis BV, Rotterdam, the Netherlands)
using a Coronary Angiography Analysis System (Pie
Medical Imaging, Maastricht, the Netherlands).
DEFINITIONS AND ENDPOINTS. The patient popula-
tion in the present study was stratiﬁed by the differ-
ence between the angiographic maximal diameterve no relationships relevant to the contents of this
, accepted July 30, 2015.
FIGURE 1 The Method to Measure QCA Proximal and Distal Dmax
The method used to measure proximal and distal Dmax with QCA is shown. In the pre-procedural angiography (A), the operator has to deﬁne
the landing zone where the scaffold will be implanted (B). Within the landing zone, the peak of the diameter function curve proximal to the
minimal lumen diameter is deﬁned as proximal (P) Dmax (C), whereas the peak diameter function curve distal (D) to the minimal lumen
diameter is deﬁned as distal Dmax (D). In this case, the proximal and distal Dmax of 2.83 and 2.96 mm led to the correct sizing of the Absorb
(3.0 mm) with regard to the vessel diameter (E). DMAXD ¼ maximal lumen diameter distal; DMAXP ¼ maximal lumen diameter proximal;
MLD ¼ minimal lumen diameter; QCA ¼ quantitative coronary angiography; RVD ¼ reference vessel diameter.
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1717and the nominal diameter of the implanted scaffold.
The selection of device size was considered “over-
sized” (scaffold oversize group) when the patient
received 1 or more devices in vessels in which both
the proximal and the distal Dmax were smaller than
the nominal size of the device. Patients who received
Absorb scaffolds in vessels with either a proximal
or a distal Dmax or both Dmax larger than the
nominal size of the device constituted the “scaffold
nonoversize group”. When a patient received 2 or
3 overlapping Absorb scaffolds in a long lesion,
the nominal size of the proximally implanted device
was compared with the proximal Dmax, whereas
the nominal size of the distally implanted device
was compared with the distal Dmax. In the cases
of device failure (n ¼ 10), the difference between
Dmax and the implanted metallic stent was calcu-
lated. An additional analysis was performed using a
different criterion (nominal scaffold diameter within0.4 or 0.5 mm of Dmax) and is presented in Online
Tables 1 and 2.
In the present analysis, the primary clinical
outcome assessed was ischemia-driven major
adverse cardiac events (ID-MACE), deﬁned as a
composite of cardiac death, any myocardial infarc-
tion (MI classiﬁed as Q-wave or non–Q-wave MI),
and ischemia-driven target lesion revascularization
(ID-TLR) by coronary artery bypass graft or percu-
taneous coronary intervention. Cardiac death was
deﬁned as any death due to a proximate cardiac
cause (e.g., MI, low-output failure, fatal arrhythmia).
Unwitnessed death and death of unknown cause
were classiﬁed as cardiac death. MI classiﬁcation and
criteria for diagnosis were deﬁned according to the
per-protocol deﬁnition. Q-wave MI was the devel-
opment of a new, pathological Q-wave. Non–Q-wave
MI was adjudicated if there was an elevation of CK
levels to $2 times the upper limit of normal with
FIGURE 2 Proximal and Distal Dmax Compared With Nominal Size of the Scaffold
The graph represents the proximal Dmax value, the distal Dmax value and the nominal size of the implanted Absorb scaffold(s) in 1,232 pa-
tients. The Dmax measurement is based on core lab assessment. According to the manufacturer, the 2.5-mm, 3.0-mm, and 3.5-mm scaffolds
cannot be dilated beyond their nominal size of 3.0 mm, 3.5 mm, and 4.0 mm, respectively. The limit of expansion of the scaffold is depicted by
a green continuous line. Theoretically, dotted red areas indicate implantation of a too “small” Absorb scaffold in a relatively large vessel, and
dotted orange areas indicate implantation of a too “large” Absorb scaffold in a relatively small vessel. Device size selection with regard to
Dmax was considered appropriate in 867 (70.4%) patients and inappropriate in 365 (29.6%) patients. Dmax ¼ maximal lumen diameter.
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1718elevated creatine kinase-myocardial band levels in
the absence of new pathological Q waves (12).
Notably, this deﬁnition of per-protocol MI was
consistently applied in all trials included in the
present analysis. Target vessel myocardial infarction
(TVMI) was deﬁned as MI that occurred in the entire
major coronary vessel proximal and distal to the
target lesion, which includes upstream and down-
stream branches and the target lesion itself. ID-TLR
was deﬁned as any repeat percutaneous interven-
tion of the target lesion or bypass surgery of the
target vessel with either a positive functional
ischemia study, ischemic symptoms, or an angio-
graphic MLD stenosis $50% by core laboratory QCA,
or revascularization of a target lesion with diameter
stenosis $70% by core laboratory QCA without either
ischemic symptoms or a positive functional study.Deﬁnite and probable scaffold thrombosis (ST) was
adjudicated according to the Academic Research
Consortium deﬁnitions (13–15). All clinical outcomes
were adjudicated by an independent clinical events
committee.
SOURCE DOCUMENT VERIFICATION AND CLINICAL
FOLLOW-UP. In the ABSORB Cohort B and ABSORB II
studies, we veriﬁed source documents in 100% of
patients through 1-year follow-up. In the ABSORB
EXTEND trial, source document veriﬁcation was
routinely performed in 100% of patients through
30-day follow-up, subsequently in a random 20% of
patients, and in 100% of all reported events for the
remaining follow-up period.
STATISTICAL ANALYSIS. All analyses were conduct-
ed using the intention-to-treat population. For the
TABLE 1 Clinical and Pre- and Post-Procedural Angiographic Characteristics
Scaffold
Oversize Group
(n ¼ 649)
Scaffold
Nonoversize Group
(n ¼ 583)
p
Value
Age, yrs 61.6  10.7 60.8  10.1 0.20
Male 73.8 (479) 75.1 (438) 0.60
Current smoker 1.7 (141) 24 (140) 0.34
Hypertension requiring treatment 67.6 (439) 67.9 (396) 0.95
Dyslipidemia requiring treatment 69.8 (453) 69 (402) 0.76
Any diabetes mellitus 24 (156) 26.2 (153) 0.39
Unstable angina 24.8 (161) 22.9 (133) 0.46
Prior history of myocardial infarction 28.1 (182) 27.8 (162) 0.95
Lesion location
Right coronary artery 21.9 (142) 33.6 (196) <0.01
Left anterior descending artery 49.8 (323) 41.9 (244) 0.01
Left circumﬂex artery or ramus 9.9 (64) 9.6 (56) 0.92
Left main coronary artery 0 (0) 0.2 (1) 0.47
ACC/AHA lesion complexity
A 1.9 (12) 2.1 (12) 0.84
B1 53.9 (349) 52.8 (307) 0.73
B2 41.2 (267) 43.5 (25) 0.45
C 3.1 (20) 1.7 (10) 0.14
TIMI ﬂow grade 0 or 1 0.6 (4) 0.2 (1) 0.38
Calciﬁcation (moderate or severe) 13.4 (87) 14.4 (84) 0.62
Angulation $45 2.6 (17) 2.2 (13) 0.71
Bifurcation 4.0 (26) 4.8 (28) 0.58
Thrombus 1.5 (10) 1.9 (11) 0.67
Pre-procedural
Reference vessel diameter, mm 2.50  0.33 2.79  0.39 <0.01
Proximal Dmax, mm 2.66  0.30 3.11  0.34 <0.01
Distal Dmax, mm 2.58  0.31 2.94  0.38 <0.01
Minimal lumen diameter, mm 1.05  0.30 1.15  0.33 <0.01
Diameter stenosis, % 57.9  10.9 58.6  10.2 0.22
Obstruction lesion length, mm 12.2  5.9 13.0  5.7 0.03
Device related
2.5-mm scaffold 8.6 (56) 13.9 (81) <0.01
3.0-mm scaffold 82.4 (535) 77.4 (451) 0.03
3.5-mm scaffold 8.9 (58) 8.8 (51) 0.92
Average nominal diameter 2.97  0.24 3.00  0.21 0.03
Post-procedural
Reference vessel diameter, mm 2.58  0.30 2.82  0.34 <0.01
Minimal lumen diameter, mm 2.19  0.28 2.37  0.31 <0.01
Diameter stenosis, % 15.3  6.5 15.9  10.2 0.09
Acute decrease, % diameter stenosis 42.5  12.5 42.5  12.4 0.98
Acute gain, mm 1.13  0.34 1.21  0.38 <0.01
Acute gain/pre-procedural RVD, mm 0.46  0.14 0.44  0.14 0.02
Bailout treatment with metallic stent 1.9 (12) 0.7 (4) 0.08
Values are mean  SD, or % (n). Clinical and pre- and post-procedural angiographic characteristics are according
to the distribution of Dmax measurements minus the nominal scaffold size in the scaffold oversize group versus
the scaffold nonoversize group.
ACC/AHA ¼ American College of Cardiology/American Heart Association lesion characteristics; Dmax ¼
maximal lumen diameter; RVD ¼ reference vessel diameter; TIMI ¼ Thrombolysis In Myocardial Infarction.
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1719present analyses, individual data were based on a
patient-level basis. Categorical variables were
compared by Fisher exact test. Continuous variables
are presented as mean  SD and were compared by
nonparametric test. Time-to-event variables are pre-
sented as Kaplan-Meier curves. To determine the in-
dependent predictors of MACE, ﬁrstly univariate
logistic regression models were constructed using the
following variables: age, male sex, current smoking,
hypertension requiring treatment, dyslipidemia
requiring treatment, any diabetes, unstable angina,
pre-procedural diameter stenosis, pre-procedural
MLD, lesion length, angulation >45, bifurcation le-
sions, calciﬁed lesions, pre-procedural visible
thrombus, Type B2/C lesions, target vessel treatment
with 2.5-mm device, treatment with overlapping
scaffolds, and scaffold implantation in a vessel with
both proximal and distal Dmax smaller than the
nominal device size. Secondly, signiﬁcant variables
(p < 0.10) in the univariate analysis were forcedly
entered into a multivariable logistic regression model
to predict for MACE. A 2-sided p value <0.05 was
considered signiﬁcant for all tests. All statistical tests
were performed with SPSS, version 22.0 for windows
(IBM, Chicago, Illinois).
RESULTS
Of a total population of 1,248 patients, pre-procedural
Dmax was assessed by the core laboratory in 1,232
(98.7 %) patients. Figure 2 displays individual values
of proximal and distal Dmax in patients who received
Absorb scaffolds of either 2.5-mm, 3.0-mm, or 3.5-mm
nominal size. The nominal size of the implanted
Absorb scaffold was larger than both proximal and
distal Dmax in 649 patients (scaffold oversize group
52.7%).
Clinical and angiographic characteristics between
the scaffold oversize group and the scaffold non-
oversize group are detailed in Table 1. The 2 groups
did not signiﬁcantly differ with regard to main base-
line clinical characteristics, whereas pre-procedural
MLD, reference vessel diameter, and both proximal
and distal Dmax were signiﬁcantly smaller in the
scaffold oversize group than in the scaffold non-
oversize group.
The scaffold oversize group was associated with a
higher risk of ID-MACE than the scaffold nonoversize
group. As illustrated in Figure 3, the graphical pre-
sentation clearly shows that a higher number of these
patients can be seen in the lower left quadrant
(scaffold oversize group) than in the other quadrants
of the graph (6.6% vs. 3.3%, p < 0.01). MACE occurred
in 46 of 760 patients when a relatively large devicesize was selected, whereas it occurred in 16 of 472
patients when a relatively small device size was
selected (6.1% vs. 3.4%, p ¼ 0.04).
The MACE and MI rates at 1 year and 2 years were
signiﬁcantly higher in the scaffold oversize group
FIGURE 3 Distribution of the Difference Between Dmax and Nominal Scaffold
Distribution of proximal and distal Dmax measurements minus nominal scaffold size in patients with or without major adverse cardiac events is shown. When the
appropriateness of scaffold size was deﬁned by nominal scaffold diameter within 0.5 mm of Dmax, the differences between the distal Dmax and nominal scaffold size are
plotted on the y-axis and x-axis, respectively. The red ﬁlled circles represent the patients who experienced ID-MACE at 1 year. The graphical presentation demonstrates
that major adverse cardiac events (MACE) were more frequently observed in patients in whom both proximal and distal Dmax were smaller than the device nominal size
(6.6% vs. 3.3%, p < 0.01) (lower left quadrant). Dmax ¼ maximal lumen diameter; ID-MACE ¼ ischemia-driven major adverse cardiac event(s).
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1720than in scaffold nonoversize group (1-year MACE:
6.6% vs. 3.3%; log-rank p < 0.01, 2-year MACE: 8.7%
vs. 5.9%; log-rank p ¼ 0.03, 1-year TVMI: 4.5% vs.
2.1%, 2-year MI: 5.5% vs. 3.0%; log-rank p ¼ 0.04),
mainly driven by a higher rate of TVMI within
1 month after the procedure (3.5% vs. 1.9%; p ¼ 0.08)
(Figure 4, Tables 2 and 3). Among the events of MI (44
of 1,232), periprocedural MI (PMI) occurred in 28 cases
(63.6%). MI occurred after 48 h in 36% of all MI
events. In the scaffold oversize group, PMI occurred
in 64% (18 cases), whereas in the scaffold nonoversize
group, the PMI rate was 35.7% (10 cases). There were
no statistically signiﬁcant differences in the incidence
of overall angiographic complications that could bedocumented at the end of the procedure for patients
who had TVMI within 1 month (3.1% vs. 1.7%;
p ¼ 0.14) (Table 3). The incidence of ST tended to be
higher in the scaffold oversize group than in the
scaffold nonoversize group (Table 2) (1.54% vs. 0.51%,
OR: 3.03 [0.83 to 11.05]; p ¼ 0.10). The acute deﬁnite
ST rate was 0.15% and 0% in the scaffold oversize
group and the scaffold nonoversize group, respec-
tively (p ¼ 1.0). Subacute and late deﬁnite ST were not
signiﬁcantly different among the 2 groups (Online
Table 3). A case of a deﬁnite early ST is shown in
Figure 5.
When the appropriateness of scaffold size was
deﬁned by nominal scaffold diameter within 0.5 mm
FIGURE 4 Time-to-Event Curves of MACE and Its Components
Time-to-event curves of MACE (A) and its components (B: death, C: target vessel MI; D: ID-TLR) at 2 years, according to study group. ID-TLR ¼ ischemia-driven target
lesion revascularization; MACE ¼ major adverse cardiac event(s); MI ¼ myocardial infarction.
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1721of Dmax, there was no statistically signiﬁcant differ-
ence inMACE between the 2 groups, (appropriate 4.5%
vs. inappropriate 6.3%; p ¼ 0.20). When the cutoff of
0.4 mm is used, there was a signiﬁcant difference in
MACE between appropriate and inappropriate scaffold
deployment (3.4% vs. 6.8%; p ¼ 0.006) (Online
Figures 1 and 2, Online Table 3).
INDEPENDENT PREDICTOR OF MACE AFTER IMPLANTA-
TION OF ABSORB SCAFFOLD(S). With multivariable
logistic regression analysis, the independent de-
terminants of 1-year MACE were: implantation of the
Absorb scaffold(s) in a vessel with both proximal and
distal Dmax smaller than the device nominal size (OR:
2.13, 95% CI: 1.22 to 3.70; p < 0.01) and overlapping
scaffolds (OR: 2.10, 95% CI: 1.17 to 3.80; p ¼ 0.01)
(Table 4).DISCUSSION
The main ﬁndings of this study are: 1) 52.7% (n ¼ 649)
of patients had an “oversize” scaffold implantation;
2) The MACE and MI rates at 1 year were signiﬁcantly
higher in the scaffold oversize group than in the
scaffold nonoversize group (MACE: 6.6% vs. 3.3%,
log-rank p < 0.01, all MI: 4.6% vs. 2.4%; log-rank
p ¼ 0.04), mainly driven by a higher rate of MI
within 1 month after the procedure (3.5% vs. 1.9%;
p ¼ 0.08); the incidence of deﬁnite ST tended to be
higher in the scaffold oversize group than in the
scaffold nonoversize group (1.54% vs. 0.51%,OR: 3.03
[0.83 to 11.05]; p ¼ 0.10); 3) The independent de-
terminants of MACE were both Dmax smaller than the
device nominal size (OR: 2.13, 95% CI: 1.22 to 3.70;
TABLE 3 Incidence o
TVMI at 12 months afte
TVMI within 1 month a
TVMI between 1 month
index procedure
Overall angiographic co
of procedure for
Side-branch occlusio
Coronary dissection
Side branch occlusio
Not relating to device
complications for
Coronary dissection
Values are % (n).
Abbreviations as in Tabl
TABLE 2 Incidence of Clinical Events at 1 Year
Clinical Outcomes
Scaffold Oversize Group
(n ¼ 649)
Scaffold Nonoversize Group
(n ¼ 583)
OR [95% CI] p Value% (n) 95% CI % (n) 95% CI
Cardiac death 0.62 (4) 0.17–1.57 0.17 (1) 0.00–0.95 3.61 (0.40–32.39) 0.38
Myocardial infarction 4.62 (30) 3.14–5.53 2.40 (14) 1.32–4.00 1.97 (1.03–3.75) 0.049
QMI 1.23 (8) 0.53–2.41 0.34 (2) 0.04–1.23 3.63 (0.77–17.14) 0.11
NQMI 3.39 (22) 2.14–5.09 2.06 (12) 1.07–3.57 1.67 (0.82–3.40) 0.17
TVMI 4.47 (29) 3.01–6.35 2.06 (12) 1.07–3.57 2.23 (1.13–4.40) 0.025
Ischemia-driven TLR 2.62 (17) 1.53–4.16 1.54 (9) 0.71–2.91 1.72 (0.76–3.88) 0.23
Composite of cardiac death, all MI, and clinically
indicated target lesion revascularization (MACE)
6.63 (43) 4.84–8.82 3.26 (19) 1.97–5.04 2.11 (1.21–3.66) <0.01
Composite of cardiac death, target vessel MI, and
clinically indicated target lesion
revascularization (DoCE)
6.32 (41) 4.57–8.47 2.92 (17) 1.71–4.63 2.25 (1.26–3.99) <0.01
Composite of all death, all MI, and all
revascularization (PoCE)
8.01 (52) 6.04–10.37 4.46 (26) 2.93–6.47 1.87 (1.15–3.03) 0.01
Scaffold thrombosis 1.54 (10) 0.74–2.82 0.51 (3) 0.11–1.50 3.03 (0.83–11.05) 0.10
Deﬁnite ST 0.92 (6) 0.34–2.00 0.51 (3) 0.11–1.50 1.80 (0.45–7.25) 0.51
Probable ST 0.31 (2) 0.04–1.11 0 (0) 0.00–1.01 NA 1.0
Possible ST 0.31 (2) 0.04–1.11 0 (0) 0.00–1.01 NA 1.0
Incidence of clinical events at 1 year are according to the distribution of Dmax measurements minus the nominal scaffold size in the scaffold oversize group versus the scaffold nonoversize group.
CI ¼ conﬁdence interval; Dmax ¼ maximal lumen diameter; DoCE ¼ device-oriented composite endpoint; MACE ¼ major adverse cardiac event(s); MI ¼ myocardial infarction; NQMI ¼ non–Q-wave
myocardial infarction; OR ¼ odds ratio; PoCE ¼ patient-oriented composite endpoint; QMI ¼ Q-wave myocardial infarction; ST ¼ scaffold thrombosis; TLR ¼ target lesion revascularization; TVMI ¼ target
vessel myocardial infarction.
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1722p < 0.01) and overlapping scaffolds (OR: 2.10, 95% CI:
1.17 to 3.80; p ¼ 0.01).
As illustrated in the scaffold oversize group in
Figure 3, proximal and distal Dmax were signiﬁcantly
smaller than in the scaffold nonoversize group
(proximal Dmax: 2.66  0.30 mm vs. 3.11  0.34 mm;
p < 0.01, distal Dmax: 2.58  0.31 mm vs. 2.94  0.38
mm; p < 0.01, respectively) (Table 1). In the popula-
tion described in the scaffold oversize group, 2.5-mm
device size scaffolds were less frequently selected
(8.6% vs. 13.9%; p < 0.01) as compared with 3.0-mmf TVMI
Scaffold
Oversize Group
(n ¼ 649)
Scaffold
Nonoversize Group
(n ¼ 583)
p
Value
r index procedure 4.5 (29) 2.1(12) 0.025
fter index procedure 3.5 (23) 1.9 (113) 0.08
and 12 months after 0.9 (6) 0.2 (1) 0.13
mplications at the end
TVMI within 1 month
3.1 (20) 1.7 (10) 0.14
n 2.3 (15) 1.4 (8) 0.29
1.1 (7) 0.3 (2) 0.18
n þ coronary dissection 0.3 (2) 0 (0) 0.50
caused angiographic
TVMI within 1 month
0.3 (2) 0.3 (2) 1.0
due to balloon dilation
e 2.scaffolds (82.4% vs. 77.4%; p ¼ 0.03). In the scaffold
oversize group, acute gain normalized for pre-
procedural reference vessel diameter was higher
(0.46  0.14 vs. 0.44  0.14; p ¼ 0.02) and bailout
treatment with metallic stents was more frequently
performed (1.9% vs. 0.7%; p ¼ 0.08) compared
with the nonoversize group (Table 1). Implanting
Absorb scaffold(s) in a vessel with both proximal and
distal Dmax smaller than the device nominal size may
cause edge dissections due to the higher balloon/
device–artery ratio during scaffold deployment.
Retrospective subanalysis (8) of the ABSORB
Cohort B study demonstrated that after implantation
of a 3.0  18-mm device, patients with a Dmax
ranging between 2.5 and 3.3 mm had better acute OCT
outcomes as compared with patients with a Dmax out
of range. The implantation of a “small” Absorb scaf-
fold in a relatively large vessel can cause incomplete
strut apposition at the edge and may be associated
with scaffold disruption (9) when aggressive post-
dilation with a larger balloon is attempted to correct
such malapposition (Figure 6A). Conversely, implan-
tation of a “large” Absorb scaffold in a relatively small
vessel can cause vessel injury or underexpansion of
the scaffold (Figure 6B).
CLINICAL OUTCOMES WITH RESPECT TO Dmax.
The present study clearly demonstrates that
implanting Absorb scaffold(s) in a vessel with both
proximal and distal Dmax smaller than the device
FIGURE 5 A Case Example of a Deﬁnite Early Thrombosis of Absorb Scaffold Implanted in the Mid-LAD
The patient received a 3.0-mm device in a too-small vessel (proximal and distal Dmax 2.15 mm and 2.32 mm, respectively [A and B]). After Absorb scaffold implantation
(C and D, arrowheads), QCA showed an excellent result with a residual DS of 9%. Fifteen days after the procedure, the patient presented with a STEMI due to early
scaffold thrombosis (E) that was treated with a manual aspiration only (F and G). DS ¼ diameter stenosis; LAD ¼ left anterior descending coronary artery; ST ¼ scaffold
thrombosis; STEMI ¼ ST-segment elevation myocardial infarction; other abbreviations as in Figure 1.
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1723nominal size is associated with a higher risk of ID-
MACE (6.6% vs. 3.3%; p < 0.01). The difference in
1-year MACE was observed in the scaffold oversize
group and was mainly driven by a higher MI
rate (4.5% vs. 2.1%; p < 0.01). Scaffold expansion
below nominal diameters can lead to a denser
polymer surface pattern and a higher polymer-to-
artery ratio (Online Figure 3). Furthermore, the
expanding radial force may be suboptimal in these
underdeployed conﬁgurations; presumably, these
unfavorable ﬁnal expansion diameters might cause
micro thrombus formation at the strut level and
side-branch occlusion. However, no statistically
signiﬁcant difference in the incidence of overall
angiographic complications could be documented at
the end of the procedure for the patients who sus-
tained MI within 1 month (scaffold oversize group:3.1% vs. scaffold nonoversize group: 1.7%; p ¼ 0.14)
(Table 3).
With multivariable logistic regression analysis, the
independent determinants of 1-year MACE were: im-
plantation of an Absorb scaffold(s) in a vessel with
both proximal and distal Dmax smaller than device
nominal size (OR: 2.13, 95% CI: 1.22 to 3.70; p < 0.01)
and overlapping scaffolds (OR: 2.10, 95% CI: 1.17 to
3.80; p ¼ 0.01) (Table 4). Of note, in a juvenile porcine
model, overlapping Absorb scaffolds showed delayed
healing on histology and with OCT assessment and
slower tissue coverage than nonoverlapping scaf-
folds. Indeed, the neoendothelial coverage of the
overlapping segments was 80.1% and 99.5% at 28 and
90 days after implantation, respectively; accordingly,
coverage in humans may need up to 18 months to be
completed (16). Among the 62 patients with MACE,
TABLE 4 Predictors of MACE After Implantation of the Absorb Scaffold(s)
Univariate Logistic
Regression
Multivariate Logistic
Regression
OR (95% CI) p Value OR (95% CI) p Value
Age, yrs 1.01 (0.98–1.03) 0.64 — —
Male 0.83 (0.47–1.46) 0.52 — —
Current smoker 0.80 (0.42–1.53) 0.51 — —
Hypertension requiring treatment 1.00 (0.90–1.10) 0.96 — —
Dyslipidemia requiring treatment 1.54 (0.84–2.83) 0.16 — —
Any diabetes mellitus 0.78 (0.42–1.46) 0.44 — —
Unstable angina 0.69 (0.35–1.34) 0.27 — —
Prior myocardial infarction 1.01 (0.99–1.04) 0.20 — —
Pre-procedural diameter stenosis, % 0.99 (0.97–1.02) 0.55 — —
Pre-procedural MLD, mm 0.76 (0.33–1.72) 0.51 — —
Obstruction length, mm 0.99 (0.94–1.04) 0.64 — —
Smallest Dmax (proximal and distal) 0.51 (0.22–1.14) 0.10 — —
Angulation $45 0.64 (0.09–4.81) 0.67 — —
Moderate/severe calciﬁcation 0.65 (0.28–1.54) 0.33 — —
Pre-procedural visible thrombus 0.94 (0.12–7.13) 0.95 — —
Bifurcation lesion CS CS — —
Type B2/C lesion 1.02 (0.61–1.71) 0.93 — —
Left anterior descending artery 0.73 (0.43–1.23) 0.24 — —
Nominal scaffold
size/post-procedural MLD
3.11 (0.73–13.16) 0.12 — —
Treatment with overlapping devices 2.08 (1.15–3.75) 0.02 2.10 (1.17–3.80) 0.01
2.5-mm device implanted 0.69 (0.27–1.75) 0.44 — —
Implanting Absorb scaffold(s) in a
vessel with both proximal and
distal Dmax smaller than
nominal size of the device
2.11 (1.21–3.66) 0.01 2.13 (1.22–3.70) <0.01
CS ¼ complete separation; ITT ¼ intention to treat; MLD ¼ minimal lumen diameter; other abbreviations as in
Table 2.
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1724MI occurred in 14 (22.6%) patients who were treated
with overlapping scaffolds and were mainly PMI
(12 [19.4%]). Thus, overlapping of scaffolds might be
a contributing factor of MACE.
PRACTICAL IMPLICATIONS OF THE SELECTION OF
APPROPRIATELY SIZED ABSORB SCAFFOLDS.
Previously, we have focused mainly on the upper
limit of 0.5 mm Dmax due to the well-known issues of
device malapposition and disruption in case of over
dilation. However, scaffold underexpansion due to
the deployment of a scaffold in a vessel with a smaller
size, may be associated with a higher post-procedural
MI rate due to several different mechanisms. The
oversized scaffold could create vessel dissection or
microperforation in a small target vessel. Alterna-
tively, the underexpansion of the scaffold may lead to
a denser polymer surface pattern and a larger strut
footprint to vessel surface area causing side branch
occlusion or microthrombus formation.
In the present study, the size selection of Absorb
scaffolds with the cutoff value of 0.5-mm Dmax has
been shown to be clinically relevant. As presented inthe Results and Online Appendix, more events were
observed when the mismatch between the device and
the vessel size was beyond 0.4 mm. It could therefore
be recommended that the device–vessel mismatch
regarding Dmax should be within 0.4 mm.
The current analysis showed that the device–vessel
mismatch regarding the pre-procedural angiography
has a clinical impact. There were no differences in
MACE in the population with a post-procedure diam-
eter stenosis $10% and <10% (MACE: 5.3% vs. 4.1%;
p ¼ 0.46) or in patients with a diameter stenosis $20%
and <20% (MACE: 5.14% vs. 4.69%; p ¼ 0.77). There-
fore, the observed relationship between device–vessel
mismatch and clinical outcomes seems to speciﬁcally
relate to pre-procedural angiographic measure-
ment. It is still unclear how far the pre-procedural
device–vessel mismatch could be corrected by post-
dilation with high-pressure or low-pressure balloons.
Currently, operators with a large experience of BRS
implantation are intuitively promoting a strategy of a
high-pressure post-dilation with a noncompliant
balloon size 0.25 or 0.5 mm larger than the nominal
size of the device. A randomized trial on post-dilation
strategy (systematic vs. nonsystematic) will be able
to clarify what the optimal implantation technique
for this polymeric coronary device is.
It has been shown that QCA underestimates coro-
nary lumen diameter, whereas OCT provides correct
assessment of lumen dimension (17). Mattesini et al.
(18,19) reported that when OCT is used to guide
and optimize Absorb scaffold implantation, post-
implantation area stenosis, minimal lumen area, and
eccentricity index were similar to those observed af-
ter deployment of second-generation metallic drug-
eluting stents. The different approach for lesion
preparation and routine use of OCT guidance during
Absorb scaffold implantation might have contributed
to these results. In addition, recent studies demon-
strated with multivariable analysis that peristent
dissections shown by OCT were independent pre-
dictors of PMI (OR: 5.3, 95% CI: 1.2 to 24.3), raising
concerns about the relationship between these mi-
nor vessel injuries and a potential higher risk of
early TVMI (20). Taking into account the weakness
of QCA for accurately measuring vessel lumen
dimension and its inability to assess incomplete
scaffold apposition and/or acute scaffold disruption,
coregistration (21) of OCT imaging and x-ray angi-
ography may be useful for optimizing the percuta-
neous treatment of coronary artery disease with
bioresorbable vascular scaffolds. In future studies, a
clinical scientiﬁc question would be whether the
pre-procedural usage of intravascular imaging could
further improve clinical outcomes.
FIGURE 6 The Potential Consequences of a Device–Vessel Mismatch Implantation
Implantation of a too “small” Absorb scaffold in a relatively large vessel can cause incomplete apposition of the device edges (A, top panel,
blue and red arrowheads). Incomplete scaffold apposition (blue and red arrow heads) and scaffold under-expansion (yellow arrowhead) are
visible in the OCT images (A, bottom panel). Implantation of a too “large” Absorb scaffold in a relatively small vessel can cause vessel injury
(B, top panel, blue and red arrowheads). Edge dissections (blue and red arrowheads) are visible in the OCT images (B, bottom panel).
ISA ¼ incomplete scaffold apposition; OCT ¼ optical coherence tomography; other abbreviations as in Figure 1.
PERSPECTIVES
WHAT IS KNOWN? QCA-Dmax–guided scaffold size selection
has been proposed to optimize the scaffold implantation proce-
dure. However, the relationship between clinical outcomes and
QCA-Dmax is unknown.
WHAT IS NEW? The device-vessel size mismatch has an impact
on clinical event after implantation of Absorb scaffold.
WHAT IS NEXT? The current results should be conﬁrmed in
large-scale randomized trials, and the mechanistic etiologies
should be further elucidated in studies using intravascular
imaging.
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1725STUDY LIMITATIONS. The current study does not
provide mechanistic data to support the occurrence of
clinical adverse events caused by sizing mismatch due
to a lack of routine intravascular imaging (e.g., intra-
vascular ultrasound, OCT, etc.). Further investigation
using intravascular imaging is needed to establish the
relationship between acutemechanistic complications
(such as underexpansion, dissection, and malap-
position, and so on) and late adverse events.
CONCLUSIONS
Selection of an appropriate scaffold size according to
the vessel Dmax showed a trend toward less frequent
ID-TLR, whereas implantation of an oversized Absorb
scaffold in a relatively small vessel may be associated
with a higher risk of MACE at 1 year. The current results
need to be conﬁrmed in the large-scale randomized
trials that are on-going, and the mechanistic etiologies
should be further elucidated in imaging studies.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Yoshinobu Onuma, Erasmus Medical Center, ’s-
Gravendijkwal 230, Rotterdam 3015CE, the Netherlands.
E-mail: yoshinobuonuma@gmail.com.
Ishibashi et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 3 , 2 0 1 5
Relation Between Bioresorbable Scaffold Sizing and Clinical Outcomes N O V E M B E R 2 0 1 5 : 1 7 1 5 – 2 6
1726RE F E RENCE S1. Serruys PW, Chevalier B, Dudek D, et al.
A bioresorbable everolimus-eluting scaffold
versus a metallic everolimus-eluting stent for
ischaemic heart disease caused by de-novo native
coronary artery lesions (ABSORB II): an interim
1-year analysis of clinical and procedural second-
ary outcomes from a randomised controlled trial.
Lancet 2015;385:43–54.
2. Serruys PW, Onuma Y, Garcia-Garcia HM, et al.
Dynamics of vessel wall changes following the
implantation of the Absorb everolimus-eluting
bioresorbable vascular scaffold: a multi-imaging
modality study at 6, 12, 24 and 36 months.
EuroIntervention 2014;9:1271–84.
3. Onuma Y, Dudek D, Thuesen L, et al. Five-year
clinical and functional multislice computed to-
mography angiographic results after coronary
implantation of the fully resorbable polymeric
everolimus-eluting scaffold in patients with de
novo coronary artery disease: the ABSORB cohort
A trial. J Am Coll Cardiol Intv 2013;6:999–1009.
4. Serruys PW, Onuma Y, Dudek D, et al. Evalua-
tion of the second generation of a bioresorbable
everolimus-eluting vascular scaffold for the
treatment of de novo coronary artery stenosis:
12-month clinical and imaging outcomes. J Am
Coll Cardiol 2011;58:1578–88.
5. Serruys PW, Ormiston JA, Onuma Y, et al.
A bioabsorbable everolimus-eluting coronary
stent system (ABSORB): 2-year outcomes and re-
sults from multiple imaging methods. Lancet
2009;373:897–910.
6. Ormiston JA, Serruys PW, Regar E, et al.
A bioabsorbable everolimus-eluting coronary
stent system for patients with single de-novo
coronary artery lesions (ABSORB): a prospective
open-label trial. Lancet 2008;371:899–907.
7. Abizaid A, Costa JR Jr., Bartorelli AL, et al. The
ABSORB EXTEND study: preliminary report of the
twelve-month clinical outcomes in the ﬁrst 512 pa-
tients enrolled. EuroIntervention 2015;10:1396–401.
8. Gomez-Lara J, Diletti R, Brugaletta S, et al.
Angiographic maximal luminal diameter and
appropriate deployment of the everolimus-eluting
bioresorbable vascular scaffold as assessed
by optical coherence tomography: an ABSORBcohort B trial sub-study. EuroIntervention 2012;8:
214–24.
9. Onuma Y, Serruys PW, Muramatsu T, et al.
Incidence and imaging outcomes of acute scaffold
disruption and late structural discontinuity after
implantation of the absorb everolimus-eluting
fully bioresorbable vascular scaffold: optical
coherence tomography assessment in the ABSORB
Cohort B trial (A Clinical Evaluation of the Bio-
absorbable Everolimus Eluting Coronary Stent
System in the Treatment of Patients With De Novo
Native Coronary Artery Lesions). J Am Coll Cardiol
Intv 2014;7:1400–11.
10. Diletti R, Serruys PW, Farooq V, et al. ABSORB
II randomized controlled trial: a clinical evaluation
to compare the safety, efﬁcacy, and performance
of the Absorb everolimus-eluting bioresorbable
vascular scaffold system against the XIENCE
everolimus-eluting coronary stent system in the
treatment of subjects with ischemic heart disease
caused by de novo native coronary artery lesions:
rationale and study design. Am Heart J 2012;164:
654–63.
11. Farooq V, Gomez-Lara J, Brugaletta S, et al.
Proximal and distal maximal luminal diameters as
a guide to appropriate deployment of the ABSORB
everolimus-eluting bioresorbable vascular scaf-
fold: a sub-study of the ABSORB Cohort B and the
on-going ABSORB EXTEND Single Arm Study.
Catheter Cardiovasc Interv 2012;79:880–8.
12. Vranckx P, Farooq V, Garg S, et al. Different
cardiac biomarkers to detect peri-procedural
myocardial infarction in contemporary coronary
stent trials: impact on outcome reporting. Heart
2012;98:1424–30.
13. Vranckx P, Kint PP, Morel MA, Van Es GA,
Serruys PW, Cutlip DE. Identifying stent throm-
bosis, a critical appraisal of the academic research
consortium (ARC) consensus deﬁnitions: a light-
house and as a toe in the water. EuroIntervention
2008;4 Suppl C:C39–44.
14. Applegate RJ, Sacrinty MT, Little WC,
Santos RM, Gandhi SK, Kutcher MA. Incidence of
coronary stent thrombosis based on academic
research consortium deﬁnitions. Am J Cardiol
2008;102:683–8.15. Mauri L, Hsieh WH, Massaro JM, Ho KK,
D’Agostino R, Cutlip DE. Stent thrombosis in ran-
domized clinical trials of drug-eluting stents. N
Engl J Med 2007;356:1020–9.
16. FarooqV, SerruysPW,HeoJH, etal. Intracoronary
optical coherence tomography and histology
of overlapping everolimus-eluting bioresorbable
vascular scaffolds in a porcine coronary arterymodel:
the potential implications for clinical practice. J Am
Coll Cardiol Intv 2013;6:523–32.
17. Tsuchida K, van der Giessen WJ, Patterson M,
et al. In vivo validation of a novel three-
dimensional quantitative coronary angiography
system (CardiOp-B): comparison with a conven-
tional two-dimensional system (CAAS II) and with
special reference to optical coherence tomogra-
phy. EuroIntervention 2007;3:100–8.
18. Mattesini A, Pighi M, Konstantinidis N, et al.
Optical coherence tomography in bioabsorbable
stents: mechanism of vascular response and
guidance of stent implantation. Minerva Car-
dioangiol 2014;62:71–82.
19. Mattesini A, Secco GG, Dall’Ara G, et al.
ABSORB biodegradable stents versus second-
generation metal stents: a comparison study of
100 complex lesions treated under OCT guidance.
J Am Coll Cardiol Intv 2014;7:741–50.
20. Porto I, Di Vito L, Burzotta F, et al. Predictors
of periprocedural (type IVa) myocardial infarction,
as assessed by frequency-domain optical coher-
ence tomography. Circ Cardiovasc Interv 2012;5:
89–96, S1–6.
21. Hebsgaard L, Nielsen TM, Tu S, et al. Co-
registration of optical coherence tomography and
X-ray angiography in percutaneous coronary
intervention. The Does Optical Coherence To-
mography Optimize Revascularization (DOCTOR)
fusion study. Int J Cardiol 2014;182C:272–8.
KEY WORDS bioresorbable scaffold,
major adverse cardiac event(s),
maximal lumen diameter
APPENDIX For supplemental ﬁgures and ta-
bles, please see the online version of this article.
